Did you mean leaf iodide?
Displaying drugs 651 - 675 of 704 in total
Piclidenoson
CF 101 (known generically as IB-MECA) is an anti-inflammatory drug for rheumatoid arthritis patients. Its novel mechanism of action relies on antagonism of adenoside A3 receptors.
CF101 is supplied as an oral drug and has an excellent safety profile. It is also being considered for the treatment of other autoimmune-inflammatory...
Investigational
Iobenzamic acid
Experimental
Norclozapine
ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia. It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.
Investigational
Acetrizoic acid
Acetrizoic acid presents the molecular formula of 3-acetamidol-2,4,6-triiodobenzoic acid and it is the first monomeric ionic compound used as an X-ray contrast agent. It was first synthesized by Wallingford in 1953 and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th,...
Withdrawn
Novo Nordisk a/S Compound
Experimental
Verubecestat
Verubecestat is under investigation for the treatment of Alzheimer's Disease, Prodromal Alzheimer's disease, and Amnestic Mild Cognitive Impairment.
Verubecestat is Merck’s investigational oral β-site amyloid precursor protein cleaving enzyme (BACE1 or β secretase) inhibitor. In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat. In the study,...
Investigational
N-Alpha-Acetyl-3,5-Diiodotyrosylglycine
Experimental
Iocarmic acid
Experimental
ACA 125
An IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies. ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of ovarian carcinomas.
This new concept of oncological immunotherapy consists of an attempt to trigger the immune system of the host...
Investigational
rGLP-1
rGLP-1 is a continuous infusion of glucagon-like peptide 1, or GLP-1, targeted for the treatment of congestive heart failure (CHF) in patients ineligible for transplant. GLP-1 is a naturally occurring hormone produced in the intestines in response to food intake.
Investigational
Liothyronine I-131
Liothyronine I-131 has been used in trials studying the treatment of Tricuspid Atresia and Heart Defects, Congenital.
Investigational
Declopramide
Investigational
Tea tree oil
Tea tree oil is an essential oil derived mainly from the Australian native plant Melaleuca alternifolia via steam distillation of the of the leaves and terminal branches . It may be referred to as Melaleuca alternifolia oil. It has been a popular ingredient in a variety of household and cosmetic...
Experimental
Nutraceutical
Lysergic acid diethylamide
Debate continues over the nature and causes of chronic flashbacks. Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence. Some say HPPD is a manifestation of post-traumatic stress disorder, not related to the direct action of LSD...
Illicit
Investigational
Withdrawn
Matched Description: … Many emotionally intense experiences can lead to flashbacks when a person is reminded acutely of the …
ADX-10061
ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.
Investigational
ISIS 113715
ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes. In early trials, ISIS 113715 induced statistically significant improvements in multiple measures of glucose control along with statistically significant
reductions in LDL-cholesterol.
Investigational
Iodoxamic acid
Radiopaque medium used in the diagnosis of gall bladder & bile duct diseases, usually as meglumine salt.
Experimental
Ioglycamic acid
Experimental
Camostat
Camostat mesylate, or FOY-305, is a synthetic serine protease inhibitor.[A193842,A193848] It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. Camostat mesylate inhibits cholecystokinin, pro-inflammatory cytokines, and serine proteases, leading to it being investigated for multiple indications including the...
Experimental
Displaying drugs 651 - 675 of 704 in total